Abstract：
UNASSIGNED: The hallmark of most patients with severe asthma is type 2 inflammation, driven by innate and adaptive immune responses leading to either allergic or non-allergic eosinophilic infiltration of airways. The cellular and molecular pathways underlying severe type 2 asthma can be successfully targeted by specific monoclonal antibodies.
UNASSIGNED: This review article provides a concise overview of the pathophysiology of type 2 asthma, followed by an updated appraisal of the mechanisms of action and therapeutic efficacy of currently available biologic treatments used for management of severe type 2 asthma. Therefore, all reported information arises from a wide literature search performed on PubMed.
UNASSIGNED: The main result of the recent advances in the field of anti-asthma biologic therapies is the implementation of a personalized medicine approach, aimed to achieve clinical remission of severe asthma. Today this accomplishment is made possible by the right choice of the most beneficial biologic drug for the pathologic traits characterizing each patient, including type 2 severe asthma and its comorbidities.
UNASSIGNED: This review article provides a concise overview of the pathophysiology of type 2 asthma, followed by an updated appraisal of the mechanisms of action and therapeutic efficacy of currently available biologic treatments used for management of severe type 2 asthma. Therefore, all reported information arises from a wide literature search performed on PubMed.
UNASSIGNED: The main result of the recent advances in the field of anti-asthma biologic therapies is the implementation of a personalized medicine approach, aimed to achieve clinical remission of severe asthma. Today this accomplishment is made possible by the right choice of the most beneficial biologic drug for the pathologic traits characterizing each patient, including type 2 severe asthma and its comorbidities.
摘要：
背景：大多数重度哮喘患者的标志是2型炎症，由先天和适应性免疫反应驱动，导致气道过敏性或非过敏性嗜酸性粒细胞浸润。特异性单克隆抗体可以成功靶向严重2型哮喘的细胞和分子途径。
方法：这篇综述文章简要概述了2型哮喘的病理生理学，随后对目前用于治疗重度2型哮喘的生物治疗的作用机制和治疗效果进行了更新评估.因此,所有报告的信息均来自在PubMed上进行的广泛文献检索.
结论：抗哮喘生物治疗领域的最新进展的主要结果是实施了个性化医疗方法，旨在实现重度哮喘的临床缓解。今天，这一成就是通过正确选择最有益的生物药物来表征每个患者的病理特征，包括2型严重哮喘及其合并症。
方法：这篇综述文章简要概述了2型哮喘的病理生理学，随后对目前用于治疗重度2型哮喘的生物治疗的作用机制和治疗效果进行了更新评估.因此,所有报告的信息均来自在PubMed上进行的广泛文献检索.
结论：抗哮喘生物治疗领域的最新进展的主要结果是实施了个性化医疗方法，旨在实现重度哮喘的临床缓解。今天，这一成就是通过正确选择最有益的生物药物来表征每个患者的病理特征，包括2型严重哮喘及其合并症。
